The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.
Kalkers
N F
NF
Department of Neurology, Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands. nf.kalkers@vumc.nl
Barkhof
F
F
Bergers
E
E
van Schijndel
R
R
Polman
C H
CH
D000328:Adult; D000368:Aged; D001284:Atrophy; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000473:pathology*; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010865:Pilot Projects; D011897:Random Allocation; D019782:Riluzole / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D019782:Riluzole